[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan E. Dickinson B.Sc., M.B.A.", "age": 56, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 128669, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 51, "title": "Executive VP & COO", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 496515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 62, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 566729, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 60, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 60, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 64, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Henry  Wheeler M.Sc.", "age": 40, "title": "Vice President of Investor Relations & Communication", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.03, "open": 1.98, "dayLow": 1.98, "dayHigh": 2.1008, "regularMarketPreviousClose": 2.03, "regularMarketOpen": 1.98, "regularMarketDayLow": 1.98, "regularMarketDayHigh": 2.1008, "payoutRatio": 0.0, "beta": 0.8, "forwardPE": 4.5111113, "volume": 43524, "regularMarketVolume": 43524, "averageVolume": 14132, "averageVolume10days": 13390, "averageDailyVolume10Day": 13390, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 193785104, "fiftyTwoWeekLow": 1.29, "fiftyTwoWeekHigh": 3.511, "allTimeHigh": 11.95, "allTimeLow": 1.29, "priceToSalesTrailing12Months": 15.335953, "fiftyDayAverage": 2.05684, "twoHundredDayAverage": 1.99808, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 154082336, "profitMargins": 0.0, "floatShares": 59218758, "sharesOutstanding": 92166898, "sharesShort": 48691, "sharesShortPriorMonth": 49023, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.0005, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.0017299999, "shortRatio": 2.32, "shortPercentOfFloat": 0.00059999997, "impliedSharesOutstanding": 95460644, "bookValue": 0.056, "priceToBook": 36.25, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -46051000, "trailingEps": -0.64, "forwardEps": 0.45, "enterpriseToRevenue": 12.194, "enterpriseToEbitda": -3.096, "52WeekChange": 0.0049505234, "SandP52WeekChange": 0.118204355, "quoteType": "EQUITY", "currentPrice": 2.03, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.20333, "targetMedianPrice": 2.61, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 60027000, "totalCashPerShare": 0.651, "ebitda": -49771000, "totalDebt": 27029000, "quickRatio": 2.081, "currentRatio": 2.208, "totalRevenue": 12636000, "debtToEquity": 525.447, "revenuePerShare": 0.15, "returnOnAssets": -0.25922, "returnOnEquity": -2.71367, "grossProfits": -30788000, "freeCashflow": -20764000, "operatingCashflow": -41096000, "revenueGrowth": -0.606, "grossMargins": -2.43653, "ebitdaMargins": 0.0, "operatingMargins": -5.23189, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "marketState": "CLOSED", "regularMarketChangePercent": 0.0, "regularMarketPrice": 2.03, "regularMarketTime": 1760126400, "fiftyTwoWeekLowChange": 0.74, "fiftyTwoWeekLowChangePercent": 0.57364345, "fiftyTwoWeekRange": "1.29 - 3.511", "fiftyTwoWeekHighChange": -1.481, "fiftyTwoWeekHighChangePercent": -0.42181715, "fiftyTwoWeekChangePercent": 0.49505234, "earningsTimestamp": 1763037000, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "earningsCallTimestampStart": 1758110400, "earningsCallTimestampEnd": 1758110400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.64, "epsForward": 0.45, "epsCurrentYear": -0.658, "priceEpsCurrentYear": -3.0851064, "fiftyDayAverageChange": -0.026839972, "fiftyDayAverageChangePercent": -0.01304913, "twoHundredDayAverageChange": 0.031919956, "twoHundredDayAverageChangePercent": 0.015975315, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.5 - Buy", "cryptoTradeable": false, "exchange": "NMS", "messageBoardId": "finmb_426137", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "regularMarketChange": 0.0, "regularMarketDayRange": "1.98 - 2.1008", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 14132, "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2025-10-11"}]